Abstracts tagged "Disease Activity and rheumatoid arthritis (RA)"

Abstract Number: 2495 • 2018 ACR/ARHP Annual Meeting
Sex Differences in the Achievement of Remission in Rheumatoid Arthritis – Choice of Disease Activity Measure Matters
Carson Maynard¹, Ted R. Mikuls², Grant W. Cannon³, Bryant R. England⁴, Gail S. Kerr⁵, Jennifer Barton⁶ and Joshua Baker⁷, ¹Division of Rheumatology, Philadelphia VA Medical Center and University of Pennsylvania, PHILADELPHIA, PA, ²Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ³Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁴Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁵Rheumatology, Washington DC VAMC and Georgetown and Howard University, Washington, DC, ⁶VA Portland Health Care System and Oregon Health and Science, Portland, OR, ⁷Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA
Background/Purpose: In rheumatoid arthritis (RA), women may be less likely to achieve clinical remission. These sex differences remain incompletely understood and might relate to differences…
Abstract Number: 2496 • 2018 ACR/ARHP Annual Meeting
Determination of the Minimally Important Difference for Interpreting the RA Multi-Biomarker Disease Activity Test Score: Impact of Diurnal and Daily Biomarker Variation on Scores Adjusted for Age, Sex and Adiposity
David Chernoff¹, P. Scott Eastman², Darl D. Flake II³, Alan J. Kivitz⁴ and Jeffrey R. Curtis⁵, ¹Crescendo Bioscience Inc., South San Francisco, CA, ²Senior Director, New Product Development, Crescendo Bioscience Inc., South San Francisco, CA, ³Myriad Genetics Inc., Salt Lake City, UT, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Previous studies have demonstrated the efficacy of a treat-to-target approach to optimize therapeutic outcomes for patients with RA using measures of clinical disease activity…
Abstract Number: 73 • 2018 ACR/ARHP Annual Meeting
Circular RNAs Expression Profile in Chinese Rheumatoid Arthritis Patients at Different Disease Activity
Huan Liu, Qibing Xie and Geng Yin, Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China
Circular RNAs Expression Profile in Chinese Rheumatoid Arthritis Patients at Different Disease ActivityBackground/Purpose: Rheumatoid arthritis (RA) is an autoimmune-mediated chronic inflammatory joint disease, that is…
Abstract Number: 543 • 2018 ACR/ARHP Annual Meeting
Disease Severity Among Bio-Naive RA Patients on Csdmards
Leslie R. Harrold^1,2, Jenny Griffith³, Heather J Litman⁴, Hua Feng², Casey A. Schlacher⁵ and Joel Kremer⁶, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC, Waltham, MA, ³AbbVie, Inc., North Chicago, IL, ⁴Corrona LLC, Waltham, MA, ⁵AbbVie Inc., North Chicago, IL, ⁶Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD) are recommended as the first-line treatment for patients with rheumatoid arthritis (RA). Guidelines recommend escalation of treatment to…
Abstract Number: 2477 • 2018 ACR/ARHP Annual Meeting
Which Is the Best Measure for Rheumatoid Arthritis Disease Activity? a Head to Head Comparison of the Six American College of Rheumatology Recommended Disease Activity Measures
Mamatha Katikaneni¹, Sunny Patel², Arina Garg², Madiha Tariq², Sebastian Wilk², Khagendra Dahal³, Robert Walter³ and Samina Hayat⁴, ¹Rheumatology, Louisiana State University Health Sciences Center, Shreveport, Shreveport, LA, ²Louisiana State University Health Sciences Center, Shreveport, Shreveport, LA, ³Medicine, Louisiana State University Health Sciences Center, Shreveport, Shreveport, LA, ⁴Rheumatology/Internal Medicine, Louisiana State University Health Sciences Center, Shreveport, Shreveport, LA
Background/Purpose: Treat-to-target is the recommended strategy for the appropriate management of Rheumatoid arthritis (RA) which involves regular assessment and monitoring of disease activity using a…
Abstract Number: 2481 • 2018 ACR/ARHP Annual Meeting
Proposal to Re-Evaluate the Definition of Low Disease Activity in Routine Assesment of Patient Index Data 3 (RAPID3) in Rheumatoid Arthritis Patients
Vivekanand Tiwari¹, Ana Maheshwari², Surjeet Dheer² and Martin J. Bergman³, ¹St John's Hospital, Springfield, IL, ²Mercy Catholic Medical Center, Philadelphia, PA, ³Drexel University College of Medicine, Philadelphia, PA
Background/Purpose: There are multiple instruments to measure rheumatoid arthritis disease activity using various patient, lab or physician parameters. Since the RAPID3 has been published, there…
Abstract Number: 444 • 2017 ACR/ARHP Annual Meeting
Do Rheumatoid Arthritis Clinical Disease Activity Index Based Treat-to-Target Treatment Decisions Always Correspond to Usual Care Treatment Decisions at Point of Care?
Rajesh Gopalarathinam¹, Maryann Kimoto² and Tarun S. Sharma³, ¹Internal Medicine, Allegheny General Hospital- Allegheny Health Network, Pittsburgh, PA, ²Internal Medicine, Allegheny General Hospital - Allegheny Health Network, Pittsburgh, PA, ³Rheumatology, Lupus Center of Excellence, Allegheny Health Network, Pittsburgh, PA
Variables Concordant decisions (71%, n=22) Discordant decisions (29%, n=9) PtGA >50% of CDAI calculation (68%, n=21) Age (mean, years) 49 51 48 Sex (%, females)…
Abstract Number: 445 • 2017 ACR/ARHP Annual Meeting
FLARE-RA Instrument Detects RA Flares Independent of Disease Activity
Taysir G. Mahmoud¹, Michelle Frits², Christine Iannaccone³, Gabriela Maica⁴, Vivian P. Bykerk⁵, Michael Weinblatt⁶ and Nancy A. Shadick⁷, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Department of Rheumatology, Allergy, and Immunology, Brigham and Women's Hospital, Boston, MA, ⁵2-005, Mt Sinai Hospital, Toronto, ON, Canada, ⁶Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Clinicians often associate the occurrence of a recent rheumatoid arthritis (RA) flare with an increase in overall disease activity. However, previous studies have shown…
Abstract Number: 1378 • 2017 ACR/ARHP Annual Meeting
Low HDL Level As a Clinical Marker of Disease Activity in Rheumatoid Arthritis Patients
Rocío Gamboa-Cárdenas¹, Manuel Ugarte-Gil², Francisco Zevallos¹, Mariela Medina¹, Zoila Rodriguez-Bellido¹, Claudia Elera-Fitzcarrald¹, Omar Sarmiento-Velasquez¹, Cristina Reategui-Sokolova¹, Victor Pimentel-Quiroz¹, José Alfaro¹, Mariano Cucho-Venegas¹, Risto Perich-Campos³ and Cesar A. Pastor-Asurza¹, ¹Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ²Peru, GLADEL, Lima, Peru, ³Rheumatology, Hospital Guillermo Almenara Irigoyen, Lima, Peru
Background/Purpose: In contrast to high evidence of HDL inflammatory function in cardiovascular risk in rheumatoid arthritis (RA) patients, there is scarce data about the total…
Abstract Number: 118 • 2016 ACR/ARHP Annual Meeting
Rates and Determinants of Persistent Patient-Physician Discordance in Global Assessment of Disease Activity in Latinos with Rheumatoid Arthritis in the United States
George A. Karpouzas¹, Elizabeth Hernandez², Chelsie Cost² and Sarah Ormseth², ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Rheumatology, Harbor-UCLA Medical Center, Torrance, CA
Background/Purpose: Patients and physicians often differ in their assessments of Rheumatoid arthritis (RA) activity [PGA and EGA respectively]. Such differences may jeopardize attainment of remission.…
Abstract Number: 535 • 2016 ACR/ARHP Annual Meeting
Examination of Diurnal and Daily Variation of the Multi-Biomarker Disease Activity (MBDA) Score in RA to Establish the Minimally Important Difference
David Chernoff¹, Rebecca J. Bolce¹, Ching Chang Hwang², Xingbin Wang¹, Alan Kivitz³ and Jeffrey R. Curtis⁴, ¹Crescendo Bioscience Inc., South San Francisco, CA, ²Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The biological variability in MBDA scores over a 24-hour period and day-to-day in patients with rheumatoid arthritis (RA) has not been well characterized. These…
Abstract Number: 560 • 2016 ACR/ARHP Annual Meeting
There Is No Further Gain from Calculating Disease Activity Score in 28 Joints with High Sensitivity Assays of C-Reactive Protein Because of High Intraindividual Variability of CRP: A Cross Sectional Study and Theoretical Consideration
Inger Marie J. Hansen^1,2,3, Rikke Asmussen⁴, Steen Antonsen⁵ and Amir Emamifar⁶, ¹Department of Reumatology, OUH, Svendborg Hospital, Svendborg, Denmark, ²University of Southern Denmark, 5000 Odense, Denmark, ³DANBIO, Glostrup, Denmark, ⁴Dep. of Rheumatology, OUH, Svendborg Hospital, Svendborg, Denmark, ⁵Biochemestry, OUH, Svendborg Hospital, 5700 Svendborg, Denmark, ⁶Rheumatology, OUH, Svendborg Hospital, 5700 Svendborg, Denmark
Background/Purpose: The threshold for reporting of C-reactive protein (CRP) differs from laboratory to laboratory. Moreover, CRP values are affected by the intra individual biological variability.[1]…
Abstract Number: 2464 • 2016 ACR/ARHP Annual Meeting
Comparison of Disease Activity Score (DAS) 28-CRP to DAS28-ESR in Patients with Active Rheumatoid Arthritis
In Ah Choi, Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea, The Republic of
Background/Purpose: Assessment of disease activity is a key part of clinical decision in rheumatology care. High disease activity presented by disease activity score 28 ((DAS28)…
Abstract Number: 2471 • 2016 ACR/ARHP Annual Meeting
What Are the Reasons of Discrepancies Between Patients and Physicians in Their Perceptions of Rheumatoid Arthritis Disease Activity and What Is the Impact of This Discordance on Remission, Function and Structure at 1 Year?
Cécile Gaujoux-Viala¹, Nathalie Rincheval², Laure Gossec³, Francis Guillemin⁴, Maxime Dougados⁵, Jean-Pierre Daures⁶ and Bernard Combe⁷, ¹Rheumatology Department, University Hospital of Nîmes and EA2415, Montpellier University, Nîmes, France, ²Biostatistic, EA 2415, Epidemiology unit, Montpellier, France, ³Paris 06 University and AP-HP, Hôpital Pitié Salpêtrière, Paris, France, ⁴University of Lorraine, Nancy, France, ⁵Paris Descartes University, Paris, France, ⁶EA2415, Nîmes, France, ⁷Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France
Background/Purpose: Patients and physicians often differ in their perceptions of rheumatoid arthritis (RA) disease activity, as quantified by the patient’s global assessment (PGA) and by…
Abstract Number: 2632 • 2016 ACR/ARHP Annual Meeting
Effects of Baseline Patient Characteristics on Baricitinib Efficacy in Patients with Rheumatoid Arthritis
Joel M. Kremer¹, Mark C. Genovese², David Muram³, Jinglin Zhong⁴, Jahangir Alam³ and Michael Schiff⁵, ¹Albany Medical College, Albany, NY, ²Stanford University Medical Center, Palo Alto, CA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Quintiles, Rockville, MD, ⁵Rheumatology, University of Colorado, Denver, CO
Background/Purpose : This analysis assessed the effects of baseline patient characteristics on the response to baricitinib treatment in patients with rheumatoid arthritis (RA) and incomplete…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].